Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 5/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481278 | 0.86 | KCNA5 (0.54) | EDNRBKCNA5KCNH2LMNAKDM4E | |
| SCHEMBL13035842 | 0.85 | EDNRB (0.48) | EDNRBALDH1A1MAPK1MAPT | |
| Hydrochloric Acid SCHEMBL3619565 | 0.83 | EDNRB (0.46) | EDNRBKCNA5KCNH2LMNAKDM4E | |
| SCHEMBL3622871 | 0.76 | EDNRB (0.45) | EDNRBKCNA5KCNH2LMNAKDM4E | |
| SCHEMBL13035840 | 0.71 | PDE9A (0.55) | EDNRBKCNA5KCNH2LMNAKDM4E | |
| SCHEMBL3874260 | 0.70 | CSF1R (0.40) | EDNRBLMNAKDM4EGRIN1GRIN2B | |
| SCHEMBL2641429 | 0.70 | ALDH1A1 (0.62) | KCNA5KCNH2LMNAKDM4EALDH1A1 | |
| SCHEMBL3622694 | 0.69 | KCNA5 (0.51) | KCNA5KCNH2KDM4EGRIN1GRIN2B | |
| SCHEMBL3622231 | 0.68 | GABRA1 (0.52) | KCNA5KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL3620578 | 0.68 | KCNA5 (0.55) | KCNA5KCNH2LMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4794445-B2 | — | — | 2011-10-19 | — | — | JP | claimed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | claimed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | claimed |
| EP-1667973-B1 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2013-12-04 | — | — | EP | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825131-B2 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| US-20070078154-A1 | Quinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-05 | — | — | US | disclosed |
| EP-1667973-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005030792-A2 | QUINOLINE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078154-A1 | Quinoline potassium channel inhibitors | KCNQ2, KCNQ1, KCNJ2 | EDNRB 2470/4885KCNA5 15/4885KCNH2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.